文献速递妇科

口服促性腺激素释放激素拮抗剂治疗子宫肌瘤:疗效参数与不良反应的系统综述与网络Meta分析

Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Uterine Myomas: A Systematic Review and Network Meta-analysis of Efficacy Parameters and Adverse Effects.
PubMed 文献 · J Minim Invasive Gynecol · 2021-12-20

该系统综述纳入5项随机对照试验共2463名子宫肌瘤相关月经过多女性,评估口服非肽类GnRH拮抗剂。网络Meta分析显示,与安慰剂相比, bleeding抑制排名前三的治疗为无反向添加的艾拉戈利600mg、400mg和200mg;所有治疗均改善生活质量,但多数升高LDL水平,安全性短期可接受但影响脂代谢。

要点

  • 与安慰剂相比,无反向添加的艾拉戈利600mg、400mg、200mg为出血抑制排名前三的治疗。
  • 无反向添加的艾拉戈利600mg的闭经风险显著高于较低剂量艾拉戈利(含或不含反向添加)及瑞卢戈利。
  • 除瑞卢戈利联合高剂量反向添加外,所有治疗均显著升高LDL水平。

核心结论

  • 口服GnRH拮抗剂似乎对肌瘤相关出血有效并能改善生活质量,短期使用安全性可接受,但影响脂代谢。

研究设计与样本

  • 系统综述与网络Meta分析,检索Web of Science和MEDLINE数据库,检索日期为2021年3月5日,限英文和人类研究。
  • 仅纳入随机对照试验,对象为子宫肌瘤相关月经过多患者,接受不同剂量口服非肽类GnRH拮抗剂(含或不含反向添加治疗)。
  • 排除将口服非肽类GnRH拮抗剂与其他非安慰剂治疗比较的研究。
  • 共纳入5项随机试验,包含2463名女性,纳入研究偏倚风险低。

主要发现

  • 与安慰剂相比,出血抑制排名前三的治疗为无反向添加的艾拉戈利600mg、400mg和200mg。
  • 无反向添加的艾拉戈利600mg的闭经风险显著高于较低剂量艾拉戈利(含或不含反向添加)及瑞卢戈利。
  • 无反向添加治疗的子宫体积变化更明显。
  • 所有治疗均与肌瘤症状相关和总体健康相关生活质量评分显著改善相关。
  • 除瑞卢戈利联合高剂量反向添加外,所有治疗均显著升高LDL水平;除无反向添加的艾拉戈利200mg外,所有治疗均显著升高LDL与HDL比值,无反向添加治疗的升高幅度最大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this systematic review is to gather and synthesize evidence regarding the use of oral gonadotrophin-releasing hormone (GnRH) antagonist for the treatment of bleeding associated with uterine myomas. DATA SOURCES: Web of Science, and MEDLINE databases were searched electronically on March 5, 2021, using combinations of the relevant Medical Subject Headings terms and keywords. The search was restricted to the English language and to human studies. METHODS OF STUDY SELECTION: Only randomized controlled trials involving patients with heavy menstrual bleeding associated with uterine myomas treated with different doses of oral nonpeptide GnRH antagonists with or without add-back therapy were included. Studies comparing oral nonpeptide GnRH antagonists with treatments other than placebo were also excluded. TABULATION, INTEGRATION, AND RESULTS: A total of 5 randomized trials including 2463 women were included in the analyses. Included studies were found to be at low risk of bias. When treatments were compared against placebo, the top 3 treatments for bleeding suppression were elagolix 600 mg, 400 mg, and 200 mg without add-back. Elagolix 600 mg without add-back therapy had a significantly higher risk of amenorrhea than lower doses of elagolix with and without add-back and relugolix as well. Uterine volume changes were more pronounced in therapies without add-back. All treatments were associated with significantly improved quality of life scores, both for myoma symptom-related and overall health-related scores. With the exception of relugolix with high-dose add-back, all treatments significantly increased low-density lipoprotein (LDL) levels. Again, all treatment modalities except for elagolix 200 mg without add-back significantly increased LDL-to-HDL ratio. The increase was highest for treatment without add-back therapy. CONCLUSION: Oral GnRH antagonists seem to be effective for myoma-associated bleeding and for improving quality of life. The safety profile is acceptable for short-term use, but lipid metabolism is affected.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Telek SB, Gurbuz Z, Kalafat E, et al. Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Uterine Myomas: A Systematic Review and Network Meta-analysis of Efficacy Parameters and Adverse Effects. J Minim Invasive Gynecol. 2021. PMID: 34942350. doi:10.1016/j.jmig.2021.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。